| P2093 | author name string | S. Murray | |
| | D. Bafaloukos | |
| | P. Kosmidis | |
| | H. Linardou | |
| | I. J. Dahabreh | |
| P2860 | cites work | Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials | Q24625201 |
| | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
| | Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 |
| | EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 |
| | Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 |
| | Operating characteristics of a rank correlation test for publication bias | Q27860653 |
| | Measuring inconsistency in meta-analyses | Q27860655 |
| | Meta-analysis in clinical trials | Q27860779 |
| | Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 |
| | Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 |
| | Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 |
| | Lung cancer in never smokers: a review | Q28287500 |
| | EGFR antagonists in cancer treatment | Q29616740 |
| | Interaction revisited: the difference between two estimates | Q29619619 |
| | Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. | Q34536780 |
| | Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 |
| | Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | Q34557318 |
| | Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer | Q34596877 |
| | Why the epidermal growth factor receptor? The rationale for cancer therapy | Q34803451 |
| | The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis | Q34986549 |
| | Use of archived specimens in evaluation of prognostic and predictive biomarkers | Q35007222 |
| | Controlling the risk of spurious findings from meta-regression. | Q35782230 |
| | EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort | Q36048238 |
| | Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis | Q36311791 |
| | Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors | Q36472193 |
| | Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. | Q36944493 |
| | Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status | Q36950271 |
| | EGFR FISH versus mutation: different tests, different end-points. | Q37119476 |
| | Molecular genetics of lung cancer in people who have never smoked | Q37206476 |
| | Issues in using progression-free survival when evaluating oncology products | Q37231532 |
| | Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 |
| | Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. | Q37325013 |
| | Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. | Q37502708 |
| | Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer | Q37661173 |
| | Population-based differences in treatment outcome following anticancer drug therapies. | Q37686610 |
| | KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 |
| | Ecological bias, confounding, and effect modification | Q38632643 |
| | A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy | Q43920708 |
| | Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer | Q44219909 |
| | Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer | Q44485092 |
| | Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database | Q45717160 |
| | Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study | Q46213605 |
| | Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. | Q46232500 |
| | Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib | Q46305423 |
| | Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study | Q46380513 |
| | Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. | Q46484712 |
| | Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study | Q46585165 |
| | Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients | Q46624747 |
| | Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. | Q46638033 |
| | Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients | Q46730203 |
| | Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay | Q46731569 |
| | Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? | Q46776120 |
| | Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. | Q51787477 |
| | Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. | Q53569591 |
| | Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis | Q56588945 |
| | Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments | Q57542907 |
| | Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens | Q59629307 |
| | Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial | Q62992066 |
| | Improved tests for a random effects meta-regression with a single covariate | Q73855792 |
| | Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer | Q79317427 |
| | The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib | Q80250628 |
| | Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer | Q80288783 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| | biomarker | Q864574 |
| | gene dosage | Q1465102 |
| | systematic review | Q1504425 |
| | meta-analysis | Q815382 |
| P304 | page(s) | 545-52 | |
| P577 | publication date | 2010-09-08 | |
| | 2011-03-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer | |
| P478 | volume | 22 | |